ADI 001
Alternative Names: ADI-001; ADI-001 CD20 gamma delta CAR-TLatest Information Update: 26 Nov 2024
Price :
$50 *
At a glance
- Originator Adicet Bio; Regeneron Pharmaceuticals
- Developer Adicet Bio
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Lupus nephritis; Non-Hodgkin's lymphoma
- Preclinical Systemic lupus erythematosus; Systemic scleroderma; Vasculitis
- Discontinued B-cell lymphoma
Most Recent Events
- 06 Nov 2024 Adicet Bio plans to initiate enrollment in clinical trial for Systemic lupus erythematosus, Systemic sclerosis, Idiopathic inflammatory myopathy, and Stiff person syndrome in the first quarter of 2025.
- 06 Nov 2024 Adicet Bio plans to initiate enrollment in clinical trial for ANCA-associated vasculitis (AAV) in the second half of 2025
- 06 Nov 2024 Adicet Bio plans to initiate enrollment in clinical trial for Lupus nephritis in the fourth quarter of 2024